Progenra Inc

Progenra Inc. is a United States-based biotechnology company operating in Malvern, Pennsylvania. The company currently employs 11 individuals and generates an annual revenue of $35 million. Progenra Inc. specializes in developing ubiquitin-based drug discovery technologies, particularly Protein Targeting Chimeras (PROTAC). These PROTAC drugs are designed to bind to both an E3 ligase and a target protein, leading to the degradation of the target protein for therapeutic purposes. This innovative approach offers advantages over traditional methods like DUB or E3 inhibitors, including a catalytic mechanism of action, reduced resistance development, and enhanced potency at lower concentrations. The company is actively engaged in preclinical development of a novel class of PROTAC molecules that have already shown promising results in cellular proof-of-concept studies. Progenra's drug discovery platform is further enhanced by internal biochemical, biological target validation programs, and medicinal chemistry/lead optimization capabilities. To learn more about Progenra Inc. and their groundbreaking research, visit their website at progenra.com.